Intermediates, process for preparing macrolide antibiotic...

Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C536S007200, C536S007400, C536S018500

Reexamination Certificate

active

06600025

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to a novel process for the preparation of clarithromycin represented by formula (I), which has broad antimicrobial activity as a macrolide antibiotic agent, and a novel intermediate that can be used for its synthesis.
BACKGROUND OF THE PRIOR ART
To date, processes for the preparation of the above-mentioned compound of formula (I) are described in Korean Patent Publication Nos. 91-5898, 91-7572, 91-2142, 95-9367, and 96-434, Korean Laid-Open Patent Publication Nos. 90-18132 and 91-7953 as well as several literatures, for example, J. Antibiotics (Vol.46, No.4, 647(1993)), J. Antibiotics (Vol.46, No.7, 1163(1993), J. Antibiotics (Vol.37, No.2, 187(1984)), Heterocycles (Vol.36, No.2, 243(1993)), and J. Antibiotics (Vol.43, No. 3, 286(1990)). These processes may be summarized in the following three ways:
<Process 1>
This process comprises protecting 3′-N,N-dimethylamino group and 2′-OH group of erythromycin 9-oxime derivative, wherein an OH group is protected, with a carbobenzyloxy(Cbz) group and then methylating the hydroxyl group at the 6 position of said compound (see Korean Patent Publication Nos. 91-5898 and 91-7572). However, this process has the disadvantages that an excess Cbz-Cl that is relatively expensive should be used, and even though the deprotection is carried out by the hydrogen reaction, this reaction is not completed on account of the catalytic poison. Further, since the methyl group of 3′-N,N-dimetylamino group of said compound has to be regenerated by methylation in the final step of the process, it has the additional disadvantages that it is difficult to perform the process, and the process is lengthy. This process may be represented by the following scheme:
<Process 2>
This process comprises protecting 3′-N,N-dimethylamino group of erythromycin 9-oxime derivative, wherein an OH group is protected, with a quaternary salt of an identical group (for example, benzyl group)(see Korean Patent Publication No.91-2142). Since the deprotection in this process is also carried out by using hydrogen as in process 1, it has the disadvantage that the reaction is not completed on account of the catalytic poison as in Process 1. This process may be represented by the following scheme:
<Process 3>
This process comprises protecting an oxime of erythromycin 9-oxime derivative with a benzyl or ketal derivative, and protecting 2′-OH group and 4′-OH group of said compound with substituted silyl groups, and then methylating a 6-OH group of said compound, and finally deprotecting a protecting group of 9-oxime and trimethylsilyl group of said 2′-O- and 4″-O-groups of said compound simultaneously in a relatively short step to obtain the desired compound.(see Korean Patent Publication Nos. 95-9367 and 96-434). In this case, the 9-oxime derivative used in the trimethylsilylation of 2′-OH and 4′-OH groups should be used in the salt free form. This process is represented by the following scheme:
In accordance with the above reaction scheme, the yield of clarithromycin synthesized from an erythromycin A is about 45 to 50%. In the cases where a benzyl derivative is used to protect an oxime for the above reaction schemes, it is difficult to perform such lengthy reactions since the deprotection is carried out by using hydrogen. Another shortcoming is that the ketal derivative, which is used to protect an oxime, has to be used excessively (with about 2 to 3 equivalents) and the total reaction time is rather lengthy. Despite of such shortcoming, the ketal derivative and trimethylsilyl groups can be simultaneously eliminated by an acid treatment.
In efforts to eliminate saprophytic matters that are produced during the 3 synthetic processes mentioned above, a purification step involving precipitation of the synthesized clarithromycin is included in the above processes. However, in most cases, there is about 10 to 20% drop in the yield. In addition, an elimination of saprophytic matters is very difficult if the saprophytic matters having similar characteristics to those of clarithromycin are present.
Accordingly, the inventors have extensively studied a new process for preparing the desired compound in order to solve the above problems of conventional methods and to increase the yield. As a result, it has been found that 1, 3-benzodithiol-2-ylium tetrafluoroborate(BDTF)(Syn. Commun., 471(1976)) represented by the following formula, which is simply synthesized from anthranilic acid, can be used as a protecting group for oxime. The present invention was made possible by means of developing a new and simple process for preparing a high yield of clarithromycin.
SUMMARY OF THE INVENTION
It is an object of this invention to provide an erythromycin A 9-O-BDT oxime intermediate represented by the following formula (III), which is useful for the synthesis of clarithromycin prepared by reacting an erythromycin A 9-oxime or hydrochloride thereof with BDTF.
Wherein, Y
1
and Y
2
represent hydrogen atoms or trimethylsilyl groups.
Additionally, the present invention provides the compound of the formula (III) (Y
1
and Y
2
are trimethylsilyl groups) crystallized in the mixed solvent comprising 5 to 10 parts by weight of acetone and 1 to 5 parts by weight of water. The ratio of the compound of said formula (III) and acetone is 2:1.
Furthermore, it is another object of this present invention to provide a process for preparation of clarithromycin, which comprises the steps of:
1) reacting an erythromycin A 9-oxime of the following formula (II) or hydrochloride thereof with 1.0 to 1.2 equivalents of 1, 3-benzodithiol-2-ylium tetrafluoroborate (BDTF) in an aprotic non polar organic solvent in the presence of 1.0 to 2.0 equivalents of pyridine to form an erythromycin A 9-O-BDT oxime derivative of the following formula (III)′ having an oxime group which is protected with a benzodithiol(BDT) group, as shown in the following scheme;
2) reacting a compound of formula (III)′ synthesized in the above step 1) with 3.0 to 5.0 equivalents of hexamethyldisilazane(HMDS) in the presence of salts such as ammonium chloride, pyridine hydrochloride, pyridine p-toluene sulfonate to form 2′-O,4″-O-bistrimethylsilyl-erythromycin A 9-O-BDT oxime derivative of formula (V), as shown in the following scheme;
3) methylating a 6-OH group of the compound of formula (V) synthesized in the above step 2) with 2.0 to 3.0 equivalents of methyl iodide in an aprotic polar solvent in the presence of a strong base to form 2′-O-,4″-O-bistrimethylsilyl-6-O methyl-erythromycin A 9-O-BDT oxime derivative of the following formula (VII) as shown in the following scheme;
4) deprotecting a compound of formula (VII) synthesized in the above step 3) to form the following formula (I).BSDA compound as shown in the following scheme and;
5) simply stirring the formula (I).BSDA compound synthesized from the step 4) in water or mixed solvent of water and water-miscible organic solvent in the presence of an inorganic salt or a base, and then filtering it to form the following scheme representing the formula (I):
DETAILED DESCRIPTION OF THE INVENTION
According to the present invention, step 1 is carried out by reacting an equivalent of erythromycin A 9-oxime representing the above formula (II) or hydrochloride thereof with 1 to 2 equivalents of BDTF in an aprotic nonpolar organic solvent in the presence of 1 to 2 equivalents of pyridine to form erythromycin A-9-O-BDT oxime derivative of the above formula (III)′ having an oxime group, which is protected with 1, 3-benzodithiol-2-ylium (BDT) group.
Step 2 is carried out by reacting the resulting compound of the formula (III)′ in the above step 1 with 3 to 5 equivalents of hexamethyldisilazane (HMDS) in the presence of salts such as ammonium chloride, pyridine hydrochloride, pyridine p-toluene sulfonate to form 2′-O-, 4″-O-bistrimethylsilyl erythromycin A 9-O-BDT oxime derivative of the above formula (V).
According to the pr

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Intermediates, process for preparing macrolide antibiotic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Intermediates, process for preparing macrolide antibiotic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intermediates, process for preparing macrolide antibiotic... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3048089

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.